Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
By J. Tepper, M. Krasna, D. Niedzwiecki, D. Hollis, C. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, R. Mayer. Journal of Clinical Oncology, 2008
1,322 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/f97b0a42879b3216120ff702781ebd95f457e56f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) (2011, background): “In Western countries, preoperative chemoradiotherapy is one of the standard treatments, but the results of the JCOG9204 study showed far better survival than that of those trials [2-4].”
- Preoperative chemoradiotherapy for esophageal or junctional cancer. (2012, neutral): “Cardiac complications§ 36/168 (21) 31/186 (17)”
- Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial (2018, background): “The sample size of ESCC was relatively small in most trials(5-11); there were usually no more than 80 cases of patients with ESCC receiving NCRT in each study.(5-13) Whether the results could be applied to East Asian countries such as China where the incidence of ESCC is extremely high remains to be”